ARTICLE
Main Tax Provisions of the French Finance Acts and the Act Against Tax Evasion and Financial Crime, Enacted in 2013
January 31, 2014
Read time: 1 min
ARTICLE
January 31, 2014
Read time: 1 min

ARTICLE / CLIENT ALERT
January 31, 2014
Read time: 5 min
Three recently passed laws will affect New York employers in 2014: (1) New York City’s paid sick time law; (2) the NYC pregnancy accommodation notice; and (3) New York State’s minimum wage and exempt salary level increases.
Last year, the New York City Council passed the New York City Earned Sick Time Act requiring certain employers to provide paid sick leave to employees. For more information, please seeSRZ’s May 14, 2013 Alert, “New York State Minimum Wage Increases and New York City’s Paid Sick Days Requirements.” The effective date of the law was dependent on the condition of the City’s economy. On Dec. 13, 2013, the New York City Independent Budget Office determined that the City’s economic index was at or above its January 2012 level. Accordingly, the law will take effect on April 1, 2014. Beginning on that date, all employers with 20 or more employees will be required to provide at least five days of paid sick leave to employees. All other employers covered under the law must provide at least five days of unpaid sick leave to employees. On Oct. 1, 2015, the paid sick leave requirements will apply to employers with 15 or more employees and employers that employ domestic workers.
Covered employers should implement leave policies that comply with the law or carefully review existing leave policies to ensure they meet the law’s requirements.
Employers are required to notify employees of their right to sick time at the commencement of the employee’s employment. The notice may be given using forms created by the New York City Department of Consumer of Affairs. The Department of Consumer Affairs has not yet released any such forms.
Additionally, on Jan. 17, 2014, New York City Mayor Bill De Blasio and City Council Speaker Melissa Mark-Viverito announced their intention to seek amendments to extend the paid leave requirement to all employers with five or more employees and expand the law in other ways, including adding grandparents, grandchildren and siblings to the definition of family member for whose medical needs an employee may take a leave under the law. The proposed bill would also allow the Mayor to shift enforcement of the law from the Department of Consumer Affairs to any City agency of the Mayor’s choosing. The amendments, which the City Council is expected to pass, are drafted to take effect on April 1, 2014.
The New York City Commission on Human Rights has issued the form notice that employers must provide to current and new employees informing of them of their rights under the new New York City pregnancy accommodation law. SeeSRZ’s Oct. 24, 2013 Alert, “Recent Employment Law Updates for New York Employers.” The notice, available on the Commission on Human Rights’ website, must be distributed to all new employees beginning Jan. 30, 2014, and existing employees must be notified of their rights prior to May 30, 2014. Under the law, employers must provide “written notice” in a “form and manner” determined by the Commission on Human Rights. The notice may also “be conspicuously posted at an employer’s place of business in an area accessible to employees.” Solely posting the notice will not necessarily comply with the law’s notice requirements.
On Dec. 31, 2013, the New York State minimum wage increased to $8.00 per hour. An updated poster can be found here. Additionally, the minimum wage will increase to $8.75 per hour effective Dec. 31, 2014, and to $9.00 per hour effective Dec. 31, 2015. In conjunction with these increases, the New York State Department of Labor has updated its regulations to bring the salary levels necessary for an exemption from overtime pay into conformity with the new minimum wage. Effective Dec. 31, 2013, the salary level needed for the administrative and executive exemptions increased from $543.75 per week to $600.00 per week. The salary level will increase to $656.25 per week effective Dec. 31, 2014 and $675.00 per week effective Dec. 31, 2015. Note that, in addition to being paid the requisite salary level, employees must still perform the duties required to qualify for the administrative and executive exemptions to apply. Allowances for tips, uniforms, meals and lodging also were increased.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the following attorneys: Mark E. Brossman, Ronald E. Richman, Holly H. Weiss, Scott A. Gold and Adam B. Gartner.
This information has been prepared by Schulte Roth & Zabel LLP (“SRZ”) for general informational purposes only. It does not constitute legal advice, and is presented without any representation or warranty as to its accuracy, completeness or timeliness. Transmission or receipt of this information does not create an attorney-client relationship with SRZ. Electronic mail or other communications with SRZ cannot be guaranteed to be confidential and will not (without SRZ agreement) create an attorney-client relationship with SRZ. Parties seeking advice should consult with legal counsel familiar with their particular circumstances. The contents of these materials may constitute attorney advertising under the regulations of various jurisdictions.
ARTICLE
January 28, 2014
Read time: 1 min

ARTICLE / CLIENT ALERT
January 28, 2014
Read time: 2 min
The Commodity Futures Trading Commission (the “CFTC”) announced its first two “made available for trade” determinations (each, a “MAT Determination”), which mandate that fund managers trade certain benchmark interest rate swaps on behalf of their funds and managed accounts through a swap execution facility (a “SEF”) or a designated contract market (a “DCM”). Once a product is subject to a MAT Determination, fund managers will not be permitted to trade such products over-the-counter. Fund managers must complete the onboarding process with an appropriate SEF or DCM if they intend to trade swaps subject to the MAT Determinations by Feb. 15 or 21, depending upon the particular interest rate swap. The MAT Determinations apply to funds that are “U.S. Persons,” which include: (1) funds that are incorporated or organized in the U.S.; (2) funds incorporated or organized inside or outside the U.S. that are managed by investment managers that have a “principal place of business” in the U.S.; and (3) funds with a “majority of U.S. investors.”
ARTICLE
January 2014
Read time: 1 min
ARTICLE
January 2014
Read time: 1 min
ARTICLE
January 24, 2014
Read time: 1 min

ARTICLE / CLIENT ALERT
January 24, 2014
Read time: 13 min
On Jan. 10, 2014, the United States Bankruptcy Court for the District of Delaware (the “Court”) in In re Fisker Automotive Holdings, Inc., et al., capped a secured creditor’s right to credit bid its $168 million claim at only $25 million (the amount it paid to purchase the claim). The decision is on appeal. While the Court stated that its decision is non-precedential, it serves as a cautionary tale for secured lenders who also are potential acquirers of a debtor’s assets in bankruptcy sales.
Loan to Fisker
Fisker Automotive Holdings, Inc. and Fisker Automotive, Inc. (collectively, “Fisker”) developed and sold luxury plug-in hybrid electric cars. To finance its business, Fisker obtained a $530 million loan commitment (the “Loan”) from the Department of Energy (“DOE”). The Loan was secured by liens on substantially all of Fisker’s assets.[1] Fisker defaulted under the Loan, and, in 2012, retained an investment banker to explore strategic alternatives and a potential sale, efforts which were unsuccessful.
DOE Sells Loan to Hybrid in Auction
The DOE decided to sell the Loan in the secondary market and hired a nationally recognized financial adviser to run an auction sale process. In October 2013, after extensive marketing efforts, five bids were submitted, including one by Wanxiang America Corporation (“Wanxiang”) and another by Hybrid Tech Holdings, Inc. (“Hybrid”), a Fisker affiliate.[2] Hybrid was the successful bidder at the auction, purchasing the Loan for $25 million.[3] At the time of the sale, there was $168 million in principal amount outstanding under the Loan.
Fisker Chapter 11 and Contested Credit Bid Sale to Hybrid
Fisker filed for Chapter 11 relief on Nov. 22, 2013. It immediately sought approval of a private sale of its assets to Hybrid and approval of debtor-in-possession financing (the “DIP Loan”) from Hybrid. The sale motion sought authority to sell Fisker’s assets to Hybrid for: (a) $75 million in the form of a credit bid of a portion of the Loan; (b) a waiver of a portion of the DIP Loan; (c) the assumption by Hybrid of certain liabilities; and (d) certain cash payments, a portion of which (approximately $500,000) would be left behind for unsecured creditors. Fisker also filed a plan of liquidation to address the administration of the remainder of its assets.
Creditors’ Committee Opposes Sale to Hybrid
The creditors’ committee (the “Committee”) was appointed in December 2013, and began litigating with Hybrid on several fronts. The Committee objected to Fisker’s sale to Hybrid arguing, among other things, that: (a) Hybrid, an insider, should be precluded from credit bidding because its principals had engaged in self-dealing and breached fiduciary duties owed to Fisker;[4] and (b) Wanxiang, which had lost the auction for the Loan, made a superior offer for Fisker’s assets.[5] The Committee also sought standing to commence an adversary proceeding against Hybrid seeking to equitably subordinate its secured claim. On Jan. 10, the Bankruptcy Court held a hearing to consider the Committee’s objection. At the hearing, the Committee and Fisker agreed to limit the issue before the court to a determination of whether Hybrid could credit bid its secured claim and, if so, whether cause existed to cap Hybrid’s right to credit bid in order to create a more competitive auction.
After hearing the parties, the Court ordered (in an oral ruling from the bench) that “there ought to be an auction and that the only way for there to be an auction was to…place a cap on the credit bidding.”[6] The Court supplemented its bench ruling on Jan. 17 with a written decision.[7]
The Court began its analysis with the text of Section 363(k) of the Bankruptcy Code, which provides that “unless the court for cause orders otherwise,” a secured creditor may credit bid (i.e., offset its secured claim against the purchase price) in a sale of its collateral. The Court found “cause” existed to cap Hybrid’s credit bid at $25 million because, if left uncapped, bidding would not just be chilled, it would be “frozen,” and there would be no auction. By capping Hybrid’s right to credit bid the Court believed that a robust auction likely would ensue. In support of its ruling, the Court cited the Third Circuit’s Philadelphia Newspapers decision where, in a footnote, the Third Circuit stated that “[a] court may deny a lender the right to credit bid in the interest of any policy advanced by the [Bankruptcy] Code, such as to ensure the success of the reorganization or to foster a competitive bidding environment.”[8]
Two additional facts appear to have influenced the Court. First, the Court was disturbed by the sale process, calling the proposed sale timetable “troublesome.”[9] The Court noted that the schedule, which straddled the Thanksgiving and December holidays, provided only 24 days for parties to challenge the sale motion and even less time for the Committee to represent the interests of unsecured creditors.[10] The Court pointed out that neither Fisker nor Hybrid ever provided a satisfactory reason why the sale of the non-operating assets required such speed, and that Hybrid’s drop dead date to purchase the assets was “pure fabrication, designed to place maximum pressure on the creditors and the Court.”[11] In sum, the Court held that Hybrid “insisted on an unfair process, i.e., a hurried process, and the validity of its secured status has not been determined.”[12]
Additionally, the Court was concerned because the validity of Hybrid’s liens on certain of Fisker’s assets is the subject of an ongoing dispute. At the start of the hearing, the Committee and Fisker agreed that Hybrid’s $168 million claim is “partially secured, partially unsecured and of uncertain status for the remainder.”[13] The Committee argued that “cause” existed to: (i) bar Hybrid from credit bidding because its lien was in dispute;[14] or, alternatively (ii) limit the amount of Hybrid’s credit bid to the $25 million that it paid for the Loan, which represented the market-tested value of the assets securing the Loan collateral.[15]
In response, Hybrid argued that: (i) even if there were unencumbered or disputed assets, the existence of such assets did notconstitute “cause” to deny a creditor the right to credit bid for its undisputed collateral;[16] and (ii) governing Third Circuit case law prohibited capping its credit bid at the value of the underlying collateral (i.e., the price it paid for the loan) and required that Hybrid be permitted to credit bid the full amount of its claim.[17]
The Court took the middle road, limiting Hybrid’s credit bid to $25 million because the extent of its lien was disputed and “[n]o one knows how much of the claim that Hybrid purchased from DOE will be allowed as a secured claim.”[18] In doing so, the Court did not provide a reason for capping Hybrid’s credit bid at the price it paid for the Loan.[19]
Even though the decision is supposedly non-precedential, secured creditors should be concerned about this decision because it could be used as a litigation tactic by committees and other parties in interest to deprive a creditor of its right to credit bid by disputing the creditor’s lien (especially in fast moving cases). Secured creditors should work with counsel early in a bankruptcy case (even before a debtor files) to consider creative and practical solutions to these potential attacks, such as: (i) providing debtor in possession financing to obtain a lien on unencumbered assets or assets that are subject to dispute as to the validity of the creditor’s prepetition liens; (ii) developing an expedited process to resolve simple lien disputes; and (iii) using non-credit bid currency to acquire unencumbered assets, such as cash or the assumption of prepetition liabilities.
This decision may have a chilling effect on future secured claim auctions and could have broader implications for the claims trading markets generally. This chilling effect will be especially felt by strategic buyers who acquire secured debt with a view towards using that debt as acquisition currency in so-called “loan to own” strategies. Compounding this effect is a small but relevant body of case law in which courts have not counted a secured creditor’s votes on a plan of reorganization when the creditor is found to have purchased the debt to obtain control of the debtor or to gain a competitive advantage.[20] This decision also may give pause to any purchaser of secured claims who intends to credit bid, who could fear that their claims would be valued at what they paid for them rather than the face amount of the claim.[21]
The Court’s reliance on the footnote from the Philadelphia Newspapers decision appears to be results oriented. While fostering “a competitive bidding environment” may be a legitimate policy objective, capping a credit bid also tramples the important policy objective of protecting a secured creditor’s property interest. One of the chief protections afforded to a secured creditor is the statutory right to credit bid. As stated by the Supreme Court, “the ability to credit-bid helps to protect a creditor against the risk that its collateral will be sold at a depressed price. It enables the creditor to purchase the collateral for what it considers the fair market price (up to the amount of its security interest) without committing additional cash to protect the loan.”[22]
Without a decision from a higher court — ultimately the Third Circuit or Supreme Court — the issue of what constitutes “cause” to cap or eliminate a credit bid will remain a hotly contested issue.
By Adam C. Harris, David M. Hillman and James T. Bentley.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
[1] See Declaration of Marc Beilinson in Support of First Day Motions, ¶ 26 [Case No. 13-13087-KG; Docket No. 2].
[2] Id.
[3] See Declaration of J.P. Hanson in Connection with Motion of Debtors for Entry of: (I) an Order (A) Approving Form and Manner of Notices and (B) Scheduling a Sale Hearing and Establishing Dates and Deadlines Related Thereto; and (II) an Order (A) Authorizing the Sale of Substantially all of the Debtors’ Assets Free and Clear of Liens, Claims, Encumbrances, and Other Interests, (B) Granting the Purchaser the Protections Afforded to a Good Faith Purchaser, and (C) Granting Related Relief [Docket No. 294].
[4] See The Official Committee of Unsecured Creditors’ Omnibus Objection to (I) the Debtors’ (A) Sale Motion, (B) DIP Financing Motion, (C) Plan of Liquidation and (D) Disclosure Statement and (II) the Allowance of Claims of Hybrid Against the Debtor [Docket No. 264] (the “Committee Obj.”), at 4. While ultimately not considered by the Court in reaching its decision, the Committee asserted that the proposed sale of Fisker’s assets to Hybrid was engineered by a director and insider of Fisker who “participated in all board meetings discussing the sale of Fisker’s assets and the sale of the Loan, all the while working with the other principals of Hybrid to implement its own plan to acquire the Loan and Fisker’s assets.”
[5] Wanxiang’s bid is $35.25 million in cash and a 20 percent equity stake in the acquired assets, whereas Hybrid’s current bid was $30 million in cash and a $25 million credit bid (reduced from $75 million set forth in the sale motion given the Court’s ruling).
[6] See Transcript of Jan. 10, 2014 Hearing (“Tr.”) 136:22-25.
[7] A copy of the Court’s Memorandum Opinion [Docket No. 483] (“Memo Op.”).
[8] See Memo Op., at 9 (citing Philadelphia Newspapers, 599 F.3d 298, 315-16 fn. 14 (3d Cir. 2010).
[9] Memo Op., at 10.
[10] Id.
[11] Memo Op., at 10, n.4.
[12] Memo Op., at 11.
[13] Memo Op., at 10. Despite Fisker’s stipulation at the beginning of the hearing that there is a dispute regarding the validity or perfection of Hybrid’s liens on certain of Fisker’s “material” assets, Fisker’s attorney later argued to the court that these assets were not very valuable or critical to the operating business. For example, Fisker’s attorney stated that Chapter 5 causes of action and commercial tort claims were not being sold and the D&O policy would remain with the estate. Fisker’s attorney characterized the disputed assets as: (i) foreign intellectual property; (ii) six certificated vehicles; and (iii) “certain inventories sitting in a foreign port.” Tr. 112:19-24. Fisker’s attorney went on to argue that a fundamental assumption in the committee’s value proposition is that Hybrid’s claims will ultimately be disallowed or avoided. Tr 113:21-114:2.
[14] Committee Obj., ¶ 41.
[15] Committee Obj., ¶ 33.
[16] Tr. 70:25-73:17. Hybrid further argued that it had provided adequate additional value (in the form of a waiver of a portion of its secured claims, additional cash, and an agreement to share proceeds from the sale of certain intellectual property) for the unencumbered and disputed assets.
[17] Limited Objection of Hybrid to Committee Obj. [Docket No. 297], ¶ 6-9 (citing Cohen v. KB Mezzanine Fund II, LP (In re SubMicron Systems Corp), 432 F.3d 448 (3d Cir. 2006) (held, although secured debt had no actual economic value, secured creditor was nonetheless entitled to credit bid its entire secured claim.).
[18] Id. (emphasis in original).
[19] The Court distinguished SubMicron stating that the validity of the claim in that case was clear, whereas here, the Court did not know how much of Hybrid’s claim was actually secured. See Mem. Op., at 11.
[20] See, e.g.,In re DBSD N. Am., Inc., 421 B.R. 133, 141-142 (Bankr. S.D.N.Y. 2009) (designating vote of secured creditor who had purchased debt as means of advancing its “strategic investment interests wholly apart from maximizing recoveries” on its claims) (aff’d Dish Network Corp. v. DBSD N. Am., Inc. (In re DBSD N. Am., Inc.), 627 F.3d 496 (2d Cir. 2010).
[21] The Court also expressed concern about the Loan auction. The Court noted that it did not “take great comfort” that the Loan was auctioned pre-bankruptcy because the Court had no oversight of that process. The Court stated that a bankruptcy auction would help it to determine whether the price paid for the Loan was “fair and reasonable and in the best interests of the debtors’ estates.” Tr. 137:6-138:4. This is somewhat surprising because secured claims often are sold in private transactions for less than par without the ostensible protections afforded by the auction of the Loan, which was conducted after an extensive marketing process by an experienced financial advisor. In sum, the Court appeared troubled that the auction of the Loan effectively determined that there would not be a bankruptcy auction and thus, the outcome of Fisker’s bankruptcy case.
[22] RadLAX, 132 S. Ct. at 2070 n.2.
This information has been prepared by Schulte Roth & Zabel LLP (“SRZ”) for general informational purposes only. It does not constitute legal advice, and is presented without any representation or warranty as to its accuracy, completeness or timeliness. Transmission or receipt of this information does not create an attorney-client relationship with SRZ. Electronic mail or other communications with SRZ cannot be guaranteed to be confidential and will not (without SRZ agreement) create an attorney-client relationship with SRZ. Parties seeking advice should consult with legal counsel familiar with their particular circumstances. The contents of these materials may constitute attorney advertising under the regulations of various jurisdictions.

ARTICLE / CLIENT ALERT
January 23, 2014
Read time: 14 min
The Centers for Medicare & Medicaid Services proposes significant changes to several key Medicare Part D Program components, such as the “any willing pharmacy” contracting requirement, that will affect all industry participants.
In its proposed rule for the Medicare Advantage (MA) and Part D Programs (Proposed Rule), the Centers for Medicare & Medicaid Services (CMS) proposes several major changes to the Medicare Part D Program, including the “any willing pharmacy” requirements. In doing so, CMS is proposing to change the way it administers several aspects of the Program, thus affecting all Program participants.
This is the second analysis of the Proposed Rule, addressing Part D Program proposals affecting Part D Plan Sponsors (Sponsors), pharmacy benefit managers (PBMs), all types of pharmacies and pharmaceutical manufacturers. A previous On the Subject addressed issues of interest for both MA Organizations and Sponsors. Forthcoming On the Subjects will focus specifically on risk adjustment data validation proposals and CMS’s proposed implementation of Section 6402 of the Affordable Care Act (ACA) and its overpayment provisions for the MA and Part D Programs.
Comments on the Proposed Rule, which was published in the Federal Register on January 10, 2014, are due to CMS by 5 p.m. EST on March 7, 2014.
Re-Interpreting the Non-Interference Provision
The Secretary of the U.S. Department of Health and Human Services, “in order to promote competition under this [Part D] and in carrying out this [Part D],” may neither “interfere with the negotiations between drug manufacturers and pharmacies and [Sponsors],” nor “require a particular formulary or institute a price structure for the reimbursement of covered part D drugs.” (42 U.S.C. § 1395w-11(i).) In its initial interpretation of the statutory language, expressed in the August 2004 proposed rule and January 2005 final rule promulgating the Part D Program regulations, CMS interpreted the non-interference provision as extending to negotiations between any of the specified parties, including Sponsor-pharmacy negotiations.
In the Proposed Rule, CMS proposes a new interpretation of the non-interference provision as applying only to pharmaceutical manufacturers’ negotiations with pharmacies and Sponsors, respectively, and would not apply the provision to negotiations between Sponsors and pharmacies. In other words, CMS would read the phrase “between drug manufacturers and pharmacies and [Sponsors]” as effectively stating “between drug manufacturers and (i) pharmacies or (ii) Sponsors.” This new interpretation of the non-interference provision would remove this limitation on CMS’s regulation of the relationship between pharmacies and Sponsors. As described below, the agency is proposing several new requirements for Sponsor-pharmacy relationships, consistent with this new interpretation.
New “Any Willing Pharmacy” Requirements for Sponsors
CMS proposes a dramatic change in its interpretation and application of two interrelated statutory provisions: that establishing Sponsors’ obligation to contract with “any willing pharmacy,” and the provision giving Sponsors the flexibility to create tiered pharmacy networks for which a lower cost-sharing is imposed for Part D drugs dispensed at certain network pharmacies.
Since the Part D Program’s inception, CMS has interpreted these two provisions as requiring Sponsors to include in their pharmacy networks any pharmacy willing to meet the Sponsors’ standard terms and conditions. Sponsors could, however, contract with a limited number of “preferred” pharmacies pursuant to alternate terms and conditions, including assignment of a lower cost-sharing obligation for covered Part D drugs. Many of the existing preferred pharmacy arrangements reflected a pharmacy’s willingness to accept lower payment rates from Sponsors or other terms in exchange for the increased customer volume resulting from the lower cost-sharing status.
CMS proposes to require Sponsors using a tiered pharmacy design to develop two sets of contracting terms and conditions—“standard” and “preferred”—for every type of similarly situated pharmacy. Every pharmacy would have the opportunity to contract under the preferred terms and conditions under CMS’s proposal, thus eliminating Sponsors’ ability to develop exclusive arrangements with select business partners. Moreover, any pharmacy offering preferred cost-sharing would be required to meet a negotiated price “ceiling” established by the Sponsor, and this ceiling price must be less than the lowest negotiated price (the “floor price”) established by the Sponsor for covered Part D drugs dispensed by pharmacies with standard cost-sharing status.
The agency also proposes to restrict the number of cost-sharing levels that Sponsors may incorporate into their benefit designs. As described in the preamble (but not the regulatory text), a retail pharmacy could dispense Part D drugs under one of three cost-sharing levels: a standard or preferred rate for dispensing a monthly prescription, and a rate for dispensing an extended days’ supply (limited to no more than three times the monthly retail rate, consistent with current CMS policy). A mail-order pharmacy would be permitted to apply a monthly or extended days’ supply cost-sharing rate, subject to the limitations discussed below.
CMS’s proposals reflect a significant departure from current Part D pharmacy network requirements, imposing new restrictions on Sponsors’ ability to design pharmacy networks that complement their Part D Plans and capitalize on unique partnership opportunities. Although the agency states that Sponsors would be “free to negotiate even deeper discounts from individual pharmacies,” some Sponsors and pharmacies may question whether there would be a sufficient return on investment for such discounted prices if the Sponsor is unable to guarantee preferential status and increased volume relative to competitors.
Proposed Conditions for Pharmacies Receiving Preferred Status
In the 2014 Call Letter, CMS expressed concern that the lower cost-sharing available at Sponsors’ “preferred” pharmacies, combined with their higher negotiated prices for certain Part D drugs, increased costs for the Medicare Program. These concerns are supported by two separate studies on Part D drug prices released by CMS in 2013 in which the agency concluded that negotiated prices for Part D drugs were not consistently lower at preferred pharmacies compared to non-preferred pharmacies. Both studies omitted from their pricing analyses, however, the effect of pharmacy rebates, similar to pharmaceutical manufacturer rebates paid independently of the point-of-sale transaction, on the aggregate drug costs Sponsors estimate and incur. CMS proposes that Sponsors require pharmacies contracting under the preferred terms and conditions to offer “better (lower) negotiated prices on all drugs in return for the lower cost-sharing.” (79 Fed. Reg. at 1976 (emphasis added).) CMS requests comments regarding whether it should take an additional step and mandate that pharmacies with preferred cost-sharing status agree to a specific percentage discount off the negotiated price as compared to the pharmacies offering standard cost-sharing.
CMS’s proposal appears to be designed to work in conjunction with the agency’s proposed prohibition on pharmacy price concessions applied after the completion of point-of-sale transactions and submission of the corresponding prescription drug event data. This proposed change to the treatment of pharmacy price concessions seems to stem from CMS’s concern that Sponsors report certain pharmacy rebates as “direct and indirect remuneration” (DIR), rather than reductions in the negotiated price. The former can have the effect of reducing Sponsors’ bids, and thus member premiums. CMS is concerned, however, that allowing these pharmacy price concessions to be reported as DIR means Sponsors’ premiums “achieve a competitive advantage not from greater efficiency, but rather from a technical difference in how costs are reported to CMS.” (79 Fed. Reg. at 1972.) By prohibiting Sponsors from accounting for pharmacy rebates as DIR, any pharmacy price concessions would have to be incorporated into the negotiated price, and thus support CMS’s proposal regarding ceiling and floor negotiated prices for pharmacies with preferred or standard cost-sharing status. CMS also proposes to re-define the term “negotiated price” to reflect this change in treatment of pharmacy price concessions.
Interestingly, CMS’s discussion does not address the implications of its proposals for beneficiaries’ premium obligations. Some industry participants argue that, by requiring pharmacy rebates to be included in the negotiated price paid at the point-of-sale, only those beneficiaries purchasing drugs from those pharmacies offering the price concessions would benefit. On the other hand, allowing pharmacy rebates to be applied against the estimated and actual allowable drug costs incurred by Sponsors may reduce Sponsors’ bid submissions—and thus the direct subsidies paid by CMS to the Sponsors and the premium obligations for all beneficiaries enrolled in their Part D Plans—and the allowable drug costs determined during the annual reconciliation.
Significant New Provisions Affecting Mail-Order Pharmacies
CMS proposes a number of prescriptive new requirements that would significantly affect mail-order pharmacies and, in many ways, limit Part D Plan Sponsors’ ability to incentivize mail-order use.
New Criteria Proposed for Part D Drug “Protected Class” Status
CMS proposes to promulgate criteria for determining categories and classes of Part D drugs that are of “clinical concern” (Protected Classes) as required by ACA § 3307 and, based on these new standards, proposes to reduce the number of Protected Classes from six to four for CY 2015.
CMS adopted two criteria to identify those Part D drug classes and categories that require protections beyond those offered by CMS’s administration of the Part D Program, including formulary oversight: (i) hospitalization, incapacity or death likely will result if access to a drug does not occur within seven days of the prescription being presented for dispensing, and (ii) more specific CMS formulary requirements would not be sufficient to ensure access to drugs necessary to treat the disease or condition. In applying these criteria for CY 2015, CMS proposes that anticonvulsants, antiretrovirals and antineoplastics all meet both of the Protected Classes criteria, and Sponsors’ formularies must include all Part D drugs in these classes. In addition, even though antipsychotics did not meet both of CMS’s proposed criteria, CMS proposes to use its exception authority to extend Protected Class status to antipsychotics for CY 2015.
Immunosuppressant and antidepressant drugs, both classes of which have been Protected Class designees since the 2006 benefit year, would not qualify for such status in CY 2015, meaning Sponsors would not be required to include on their formularies every Part D drug in these classes. CMS concluded that although hospitalization, persistent significant disability or incapacity, or death would likely will result if initial administration of the drugs in these classes does not occur within seven days of when the prescription is presented to be filled, the two drug classes do not meet the second criteria because CMS formulary requirements would suffice to meet the clinical drug-and-disease-specific applications.
As a result of the greater flexibility Sponsors will have in formulary development, the elimination of Protected Class status for immunosuppressants and antidepressants has the potential to affect entities at all stages of the drug distribution process, including drug manufacturers, Plan Sponsors, PBMs, pharmacies and beneficiaries. That said, CMS’s projections suggest that the initial financial effect may be minimal. CMS projects that its proposal to reduce the number of classes of clinical concern would generate savings of $720 million from CY 2015 to CY 2019, but $0 in savings for CY 2015; furthermore, “most” of the projected savings from CY 2016 to CY 2019 would be generated from the antipsychotic class, for which removal of Protected Class status has been delayed. Thus, unless and until such time as CMS removes Protected Class status from antipsychotics, the financial effect of the proposal may be limited and may very well be less than CMS’s stated projection of $720 million.
Affiliated Pharmacies and Other Proposals with Business Implications
CMS sets out numerous other proposals relating to other aspects of the Part D Program, including CMS’s proposal to prohibit pharmacies that are affiliated with a Sponsor from waiving cost-sharing obligations under the plan benefit package. The prohibition would apply even if the cost-sharing waiver is permissible under guidance from the Office of the Inspector General and CMS’s Medicare Prescription Drug Benefit Manual, such as for low-income subsidy-eligible individuals. The agency’s proposal is based on the premise that waiver of the cost-sharing obligation by the pharmacy equates to a waiver of the cost-sharing obligation by the affiliate Sponsor, and the latter is prohibited by the “uniform benefit” requirement. Notably, CMS’s proposal to impute to the Sponsor the cost-sharing waiver of its affiliate pharmacy is triggered automatically based solely on the related status of the two entities and regardless of the particular circumstances of the entities’ relationship, respective operations or the Sponsor’s bid submissions. The proposal also has potential to cause significant confusion for beneficiaries, who may not be aware of any corporate affiliation and therefore may not understand why certain pharmacies may waive a cost-sharing obligation while others may not.
Another example of CMS proposals is adoption of more stringent standards for new applicants to sponsor Part D Plans, including requirements regarding past experience and new testing of system capabilities post-application cycle. In both instances, Program newcomers would have to demonstrate to CMS the capability to administer prescription drug benefits based on past experience (of either itself, an affiliate or a contractor) prior to receiving a contract to participate under the Program.
Conclusion
The Proposed Rule reflects CMS’s dramatically different perspectives on prescription drug benefit administration compared to those held by the agency nine years ago, including on the role of mail-order pharmacies, relationships between Sponsors and pharmacies generally, and other aspects of Part D Plan administration. The current “way of doing business” under Part D likely will change significantly with CY 2015, and Sponsors and their partners likely will have mere weeks to respond to changes promulgated in the final rule and the June 2, 2014, bid deadline. Advance planning for potential changes and strategies for effectively and efficiently allocating resources will be critical for legal and compliance departments to address the various changes that are on the horizon.
ARTICLE
January 22, 2014
Read time: 1 min